Orchestra Appoints New Chief Financial Officer and Chief Operating Officer to Accelerate Next Phase of Growth
NEW YORK--(BUSINESS WIRE)--#O2Investment--Orchestra (www.orchestraco.com), a strategic communications and marketing company built for…
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial…
Kia Wins Gold at PR Awards AsiaPacific 2025 for PR Communication Promoting Global Awareness of Ocean Plastic Cleanup
Kia Global PR Group wins Gold award in Environmental category at PR…
CuriosityStream Reaffirms Special One-Time Cash Dividend of $0.10 Per Share
Dividend Record Date is Today, June 13, 2025 SILVER SPRING, Md.--(BUSINESS WIRE)--CuriosityStream…
Cyber Media Tour with AITO Concludes: Reaffirming Commitment to Global New Luxury Mobility
CHONGQING, China, June 12, 2025 /PRNewswire/ -- From June 10 to 12, …
Asia Tech x Singapore 2025 Recap
SINGAPORE, June 10, 2025 /PRNewswire/ -- At the recent ATxSummit, the apex event…
NYSE Content Advisory: NYSE, Money20/20, FINTECH.TV, and Cheddar create “Taking Stock”
NEW YORK, June 3, 2025 /PRNewswire/ -- The New York Stock Exchange…
Informa TechTarget Wins 52 Prestigious Online Editorial Awards
The Company’s world-class editorial teams were recognized by the Azbee and Jesse…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…